Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Li MC, Coumar MS, Lin SY, Lin YS, Huang GL, Chen CH, Lien TW, Wu YW, Chen YT, Chen CP, Huang YC, Yeh KC, Yang CM, Kalita B, Pan SL, Hsu TA, Yeh TK, Chen CT, Hsieh HP.
Li MC, et al. Among authors: hsieh hp.
J Med Chem. 2023 Feb 23;66(4):2566-2588. doi: 10.1021/acs.jmedchem.2c01434. Epub 2023 Feb 7.
J Med Chem. 2023.
PMID: 36749735
Free PMC article.